MENLO PARK, Calif.—Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company, has reported financial results for the first quarter ended March 31, 2026. In Q1, revenue was $19.7 million, an increase of 13 percent compared with the same period in the prior year. Interventional Glaucoma revenue was $18.3 million, an increase of 7 percent compared with the same period in 2025. The company attributed this improvement to an increase in both ordering accounts and average selling prices, slightly offset by lower utilization per account.
